Gene · 7307
Papers3,382
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 3,382
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M. | Blood Cancer J | 2023 | 38123548 | PubTator, text mining | PubMed |
| NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy. | Cell Rep Med | 2023 | 38118408 | PubTator, text mining | PubMed |
| RBFOX2 deregulation promotes pancreatic cancer progression and metastasis through alternative splicing. | Nat Commun | 2023 | 38114498 | PubTator, text mining | PubMed |
| Role of epithelial splicing regulatory protein 1 in cancer progression. | Cancer Cell Int | 2023 | 38110955 | PubTator, text mining | PubMed |
| Whole-genome sequencing reveals the molecular implications of the stepwise progression of lung adenocarcinoma. | Nat Commun | 2023 | 38102134 | PubTator, text mining | PubMed |
| Assessment of 2022 European LeukemiaNet risk classification system in real-world cohort from China. | Cancer Med | 2023 | 38098254 | PubTator, text mining | PubMed |
| Negative Impact of TET2 Mutations on Long-Term Survival After Transcatheter Aortic Valve Replacement. | JACC Basic Transl Sci | 2023 | 38093739 | PubTator, text mining | PubMed |
| AI-assisted proofreading of RNA splicing. | Genes Dev | 2023 | 38092520 | PubTator, text mining | PubMed |
| Role of loss and skew of X chromosome inactivation for developing myelodysplastic syndrome in patients with Klinefelter syndrome: A brief review of the literature. | Leuk Res Rep | 2023 | 38076633 | PubTator, text mining | PubMed |
| Hotspots of Somatic Genetic Variation in Pituitary Neuroendocrine Tumors. | Cancers (Basel) | 2023 | 38067388 | PubTator, text mining | PubMed |
| Review and Updates on Systemic Mastocytosis and Related Entities. | Cancers (Basel) | 2023 | 38067330 | PubTator, text mining | PubMed |
| Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial. | Front Immunol | 2023 | 38054008 | PubTator, text mining | PubMed |
| [Mutation pedigree and treatment selection of Erdheim-Chester disease]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 38049347 | PubTator, text mining | PubMed |
| [Clinical characteristics and prognostic implications of RAS mutations in newly diagnosed acute myeloid leukemia with normal karyotype based on next-generation sequencing analysis]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 38049321 | PubTator, text mining | PubMed |
| [Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023)]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 38049312 | PubTator, text mining | PubMed |
| Unleashing the potential of catalytic RNAs to combat mis-spliced transcripts. | Front Bioeng Biotechnol | 2023 | 38047291 | PubTator, text mining | PubMed |
| High cell-free DNA is associated with disease progression, inflammasome activation and elevated levels of inflammasome-related cytokine IL-18 in patients with myelofibrosis. | Front Immunol | 2023 | 38035089 | PubTator, text mining | PubMed |
| Noncoding rules of survival: epigenetic regulation of normal and malignant hematopoiesis. | Front Mol Biosci | 2023 | 38028538 | PubTator, text mining | PubMed |
| Analysis of the clinical characteristics and prognosis of adult de novo acute myeloid leukemia (none APL) with PTPN11 mutations. | Open Med (Wars) | 2023 | 38025540 | PubTator, text mining | PubMed |
| Outcomes of venetoclax combined with homoharringtonine and cytarabine in fit adults patients with de novo adverse-risk acute myeloid leukaemia: A single-centre retrospective analysis. | EJHaem | 2023 | 38024627 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7307/papers?page=15